Arvinas, Inc. (NASDAQ:ARVN) Stock Has Average Price Target of $14.55

Arvinas, Inc. (NASDAQ:ARVN) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $15.40.

Several equities research analysts have recently weighed in on ARVN shares. Morgan Stanley set a $10.00 price objective on Arvinas in a research note on Monday, August 10th. Evercore set a $14.00 target price on Arvinas in a report on Monday, August 10th. Wedbush raised their target price on Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen raised Arvinas from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings raised Arvinas from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Arvinas in the 2nd quarter worth approximately $48,000. Quantbot Technologies LP bought a new stake in Arvinas during the 2nd quarter worth approximately $85,000. Corient Private Wealth LP acquired a new stake in Arvinas during the 2nd quarter valued at $95,000. Pale Fire Capital SE acquired a new stake in Arvinas during the 2nd quarter valued at $99,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Arvinas during the 2nd quarter valued at $112,000. 95.19% of the stock is owned by institutional investors.

Arvinas Stock Down 0.3%

NASDAQ ARVN opened at $6.82 on Thursday. The stock has a market cap of $440.03 million, a P/E ratio of 68.21 and a beta of 1.80. The company’s 50-day simple moving average is $8.48 and its 200 day simple moving average is $8.84. Arvinas has a twelve month low of $6.74 and a twelve month high of $14.51.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $2.95. The firm had revenue of $249.70 million during the quarter, compared to analyst estimates of $60.71 million. Arvinas had a net margin of 2.94% and a return on equity of 1.91%. The company’s quarterly revenue was up 1014.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.84) earnings per share. Research analysts anticipate that Arvinas will post 0.05 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary PROTAC targeted protein degradation platform to design small-molecule therapies intended to direct unwanted proteins to the cell’s natural disposal system.

Arvinas’ programs have primarily focused on oncology. Its lead investigational program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer.